Trial Profile
A phase 1b study of SENS-300 to protect the inner ear from the toxicity of certain drugs and thus prevent balance disorders and loss of hearing
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2015
Price :
$35
*
At a glance
- Drugs SENS 300 (Primary)
- Indications Ear disorders; Hearing loss
- Focus Therapeutic Use
- 25 Aug 2015 New trial record
- 30 Mar 2015 According to Sensorion media release, company is planning to initiate this trial in 2016.